Responses
Infectious diseases
Protocol
Prospective, randomised, parallel-group, open-label study to evaluate the effectiveness and safety of IMU-838, in combination with oseltamivir, in adults with COVID-19: the IONIC trial protocol
Compose a Response to This Article
Other responses
No responses have been published for this article.